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Abstract
Background: Early and appropriate antibiotic dosing is associated with improved clinical outcomes in critically ill
patients, yet target attainment remains a challenge. Traditional antibiotic dosing is not suitable in critically ill
patients, since these patients undergo physiological alterations that strongly affect antibiotic exposure. For beta-
lactam antibiotics, the unbound plasma concentrations above at least one to four times the minimal inhibitory
concentration (MIC) for 100% of the dosing interval (100%ƒT > 1–4×MIC) have been proposed as pharmacodynamic
targets (PDTs) to maximize bacteriological and clinical responses. The objectives of this study are to describe the
PDT attainment in critically ill patients and to identify risk factors for target non-attainment.
Methods: This prospective observational study was performed in two ICUs in the Netherlands. We enrolled adult
patients treated with the following beta-lactam antibiotics: amoxicillin (with or without clavulanic acid), cefotaxime,
ceftazidime, ceftriaxone, cefuroxime, and meropenem. Based on five samples within a dosing interval at day 2 of
therapy, the time unbound concentrations above the epidemiological cut-off (ƒT > MICECOFF and ƒT > 4×MICECOFF)
were determined. Secondary endpoints were estimated multivariate binomial and binary logistic regression models,
for examining the association of PDT attainment with patient characteristics and clinical outcomes.
Results: A total of 147 patients were included, of whom 63.3% achieved PDT of 100%ƒT > MICECOFF and 36.7%
achieved 100%ƒT > 4×MICECOFF. Regression analysis identified male gender, estimated glomerular filtration rate
(eGFR) ≥ 90 mL/min/1.73 m2, and high body mass index (BMI) as risk factors for target non-attainment. Use of
continuous renal replacement therapy (CRRT) and high serum urea significantly increased the probability of target
attainment. In addition, we found a significant association between the 100%ƒT > MICECOFF target attainment and
ICU length of stay (LOS), but no significant correlation was found for the 30-day survival.
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Conclusions: Traditional beta-lactam dosing results in low target attainment in the majority of critically ill patients.
Male gender, high BMI, and high eGFR were significant risk factors for target non-attainment. These predictors,
together with therapeutic drug monitoring, may help ICU clinicians in optimizing beta-lactam dosing in critically ill
patients.
Trial registration: Netherlands Trial Registry (EXPAT trial), NTR 5632. Registered on 7 December 2015.
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Key messages
 Less than two-thirds of our study population
achieved the 100% ƒT >MICECOFF target, and only
in one-third the 100% ƒT > 4×MICECOFF target was
achieved.
 Male gender, high BMI, and eGFR ≥ 90mL/min/
1.73 m2 were significantly associated with target
non-attainment, while the use of CRRT and high
serum urea increased the probability of target
attainment.
 For the 100% ƒT >MICECOFF regression model,
target non-attainment was significantly associated
with the clinical outcome ICU length of stay, but no
significant association was found for the 30-day
survival.
Introduction
Large multicenter studies have reported antibiotic use in
64 to 71% of patients during their stay in the intensive
care unit (ICU) [1, 2]. To adequately prevent and treat
severe infections in critically ill patients, it is important
that patients are treated with an appropriate dosing regi-
men of antibiotics [3–5]. However, dose-finding studies
typically only include non-ICU populations. Various
studies have shown that pathophysiological changes re-
lated to critical illness (i.e., altered fluid status, changes
in serum albumin concentrations, renal and hepatic dys-
function, systemic inflammatory response syndrome, and
microvascular failure) substantially change the pharma-
cokinetics (PK) and thereby the exposure to antibiotics
[6, 7]. Moreover, critically ill patients represent a highly
heterogeneous population with a wide distribution of pa-
tients’ ages, severities of illness, co-morbidities, source of
infections, and outcomes [8]. These challenging condi-
tions make it difficult to achieve optimal exposure in
critically ill patients when using standard dosing regi-
mens for beta-lactam antibiotics.
Beta-lactam antibiotics are amongst the most com-
monly used antibiotics in the ICU setting. These anti-
biotics exhibit time-dependent bacterial killing.
Successful outcome is associated with the percentage
of time (T) of the dosing interval in which the un-
bound (free, ƒ) serum antibiotic concentration
remains above the minimum inhibitory concentration
(ƒT >MIC). For these antibiotics, the ƒT >MIC value
needed for bactericidal activity is between 40 and 70%
in in vivo infection models [9, 10], although clinical
data suggests optimal efficacy is achieved at 100%
ƒT >MIC in critically ill patients [10–12]. Patients
achieving 100% ƒT >MIC have significantly higher
rates of clinical cure and bacteriological eradication
[12–15]. To maximize the probability of clinical effi-
cacy in critically ill patients, unbound plasma concen-
tration from one up to four times the MIC for 100%
of the dosing interval (100%ƒT > 1–4×MIC) has been
identified as pharmacodynamic targets (PDTs) [16–
19]. Further increasing the exposure does not appear
to increase the rate or extent of bacterial killing [20].
Target attainment is reported in only 40 to 60% of crit-
ically ill patients treated with beta-lactam antibiotics [21,
22]. That said, achieving the high ICU targets is not easy,
particularly when conventional beta-lactam dosing regi-
mens are used. Simply increasing the standard dosing for
this group of antibiotics in all critically ill patients is not
an optimal strategy, since high dosing regimens might re-
sult in trough levels associated with overexposure and tox-
icity [23]. Thus, it appears necessary to individualize beta-
lactam dosing regimens in critically ill patients. Accord-
ingly, identifying patients at risk could prompt clinicians
to consider more individualized dosing regimens and
regular therapeutic drug monitoring (TDM).
To our knowledge, only a few other studies have
attempted to quantify patient characteristics as potential
predictors for beta-lactam antibiotics target attainment
in critically ill patients [14, 24–27]. In some of these
studies, limited numbers of patients and/or different
beta-lactam antibiotics were investigated, while in only
two of these studies, target attainment and relevant fac-
tors associated with clinical outcomes were investigated
[24, 27]. However, the relationship between target attain-
ment and the clinical outcomes ICU length of stay
(LOS) and mortality has not yet been clarified. There-
fore, the goals of this study are to determine the preva-
lence of target attainment of six frequently used beta-
lactam antibiotics in ICUs in Europe and to identify risk
factors and clinical outcomes associated with target non-
attainment.
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Methods
Study design
This prospective, observational, two-center pharmaco-
kinetics/pharmacodynamics (PK/PD) study was per-
formed in the ICU departments of the Erasmus
University Medical Center and Maasstad Hospital, Rot-
terdam, the Netherlands. The study protocol (EXPAT,
NL53551.078.15) was approved by the Erasmus MC
Medical Ethics Committee.
Study population and size
All patients admitted to the ICU between January 2016
and June 2017 and treated for a (presumed) infection
with intravenous amoxicillin (with or without clavulanic
acid), cefotaxime, ceftazidime, ceftriaxone, cefuroxime,
or meropenem were assessed for inclusion. Eligible for
enrollment were patients (1) aged ≥ 18 years, (2) ex-
pected ICU stay > 72 h, and (3) intravenous intermittent
therapy of the study antibiotics. Initiation of study anti-
biotics, dosage, and duration of therapy were selected
during a daily routine multidisciplinary consultation be-
tween the attending physician and an infectious disease
specialist. Patients were excluded if (1) written informed
consent was not obtained, (2) antibiotics were stopped
before sampling, or (3) admitted to the ICU for burn in-
juries. Patient information was collected, including
demographic data, clinical data, laboratory data, and
antibiotic dosing data during hospitalization within the
first 3 days after the start of the antibiotic therapy.
A formal sample size calculation was not needed be-
cause of the descriptive and noncomparative setting of
this study. A priori in our protocol, it was likely that at
least for four of the target antibiotics a minimum of 20
patients could be included based on prescribing data in
our study sites. For the analysis of PDT attainment and
associated clinical outcomes, a sample size of at least
140 was anticipated to be adequate [28].
Sample collection and analysis
On day 2 after the start of antimicrobial therapy, in total,
five venous blood samples were collected at 15–30 min
before the start of a dose (trough concentration, Cmin),
15–30min (peak concentration, Cmax), 1 h and 3 h after
the end of infusion, and at 15–30min before the start of
the next dose (second Cmin). The exact sampling times
and the dosage administered were recorded. Blood sam-
ples were stored at 2–8 °C directly after drawing to
maintain the integrity and centrifuged at 3000 rpm for 6
min within 24 h after collection. The plasma was trans-
ferred to cryo-vials for frozen storage (− 80 °C) until ana-
lysis. Plasma concentrations were determined by a
multi-analyte UPLC-MS/MS [29]. The method was com-
prehensively validated according to the Food and Drug
Administration (FDA) guidance on bioanalytical method
validation [30]. All observed concentrations were cor-
rected for protein binding in critically ill patients, using
average plasma protein binding (PPB) values [31]. Non-
compartmental PK analysis of the plasma concentra-
tion–time data was performed using PKSolver (version
2.0) [32].
Primary endpoints
The PK/PD endpoints were the unbound concentration
above the MIC at 100% (ICU target) of the dosing inter-
val (ƒT >MIC and ƒT > 4×MIC). The percentage ƒT >
MIC was determined by calculating the intercept of the
MIC values with the concentration–time curve. For each
of the antibiotics, the epidemiological cut-off (ECOFF)
of the presumed pathogens, i.e., the highest MIC for
organisms devoid of phenotypically detectable acquired
resistance mechanisms, as defined by the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST), was used [33]. The following EUCAST epi-
demiological cut-off (MICECOFF) values were used:
amoxicillin 8 mg/L (Enterobacterales), cefotaxime 4mg/
L (Staphylococcus aureus), ceftazidime 8mg/L (Pseudo-
monas aeruginosa), ceftriaxone 0.5 mg/L (Enterobacter-
ales), cefuroxime 8mg/L (Escherichia coli), and
meropenem 2mg/L (Pseudomonas aeruginosa). To as-
sess the suitability of the empirical fixed dosing regimens
considering ƒT >MIC and ƒT > 4×MIC, a MIC distribu-
tion of 0.03125–128 mg/L was tested for target attain-
ment for each of the antibiotics.
Secondary endpoints
We defined ICU length of stay (LOS) and 30-day sur-
vival from the start of therapy (enrollment) as our sec-
ondary endpoints. Factors likely to contribute to these
two outcomes were analyzed for association based on
clinical relevancy and previously described relationships
[14, 24–27]. These included patient characteristics (age,
gender, body mass index (BMI)), illness severity score
(Sequential Organ Failure Assessment (SOFA) score at
the start of target antibiotic), serum albumin, serum
urea, sepsis, estimated glomerular filtration rate (eGFR
≥ 90mL/min/1.73 m2), and presence of continuous renal
replacement therapy (CRRT).
Statistical analysis
All statistical analyses were performed using IBM-SPSS
(version 24.0, IBM Corp., New York, NY, USA) and R
software (version 3.3.3, R Project for Statistical Comput-
ing). Normality was assessed using the Shapiro–Wilk
test. We analyzed our data using the following three
steps. First, categorical variables were expressed as fre-
quencies (percentages), and continuous variables were
described as median values with the interquartile range
(IQR; 25–75th percentile). Differences in categorical
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variables were calculated using Pearson chi-square test
or Fisher’s exact test as appropriate. The Mann–Whit-
ney U test was used to compare continuous variables.
For our primary outcome, i.e., PDT attainment, we es-
timated multivariate binary logistic regression analyses
and present the odds ratios (ORs) and 95% confidence
intervals (95% CI). We included SOFA score at inclusion
in the multivariate analysis to control for all our regres-
sions for clinically and relevant baseline characteristics.
For our secondary outcomes, we estimated multivari-
ate negative binomial regression and binary logistic re-
gression models examining the association of PDT
attainment with ICU LOS and 30-day survival, respect-
ively. For these regressions, we present the ORs and 95%
CI. Statistical significance was accepted at p ≤ 0.05.
Results
Overall, a total of 147 patients were included in the
study, and 712 serum samples were analyzed. Baseline
patient demographic and clinical characteristics, strati-
fied by the target attainment, are summarized in Table 1.
The median patient age was 63 years, and 61% of the pa-
tients were male. The median ICU LOS was 9 days, and
30-day all-cause mortality rate was 19.7%.
Pharmacokinetic parameters
Box-and-whisker plots of unbound trough (ƒCmin)
plasma concentrations observed for the different antibi-
otics are shown in Fig. 1, and peak (ƒCmax) plasma con-
centration plots can be found in Additional file 1. Large
inter-patient variability was observed in the plasma con-
centration of the various antibiotics, e.g., a ƒCmin of cefo-
taxime ranging from 0.14 to 26 mg/L. Detailed data
describing the pooled antibiotic dosing and PK/PD indi-
ces are provided in Additional file 2.
Target attainment
The proportions of patients achieving the PDT of 100%
ƒT >MICECOFF and 100% ƒT > 4×MICECOFF were 63.3%
(93/147) and 36.7% (44/147), respectively (Table 1 and
Additional file 2). Compared to patients who did attain
the target, younger male patients with higher creatinine
clearance, higher serum albumin, higher white blood cell
count, higher length, and lower urea and those who re-
ceived concomitant antibiotics were more likely not to
achieve the PDT. Moreover, 45.7% (21/46) and 31% (16/
51) of those with an eGFR ≥ 90mL/min /1.73 m2 at
baseline and day 2 achieved the 100% ƒT >MICECOFF
target, respectively. Of all patients, twenty-eight (19%)
patients were treated with CRRT. Although not statisti-
cally significant, there was a noticeable clinically signifi-
cant difference in the number of patients treated with
CRRT between the groups who did and did not achieve
the PDT, respectively 23.7% and 12.1% (p = 0.06). The
rates for 100% ƒT >MICECOFF target attainment for
amoxicillin, cefotaxime, ceftazidime, ceftriaxone, cefurox-
ime, and meropenem were 44.4%, 57.0%, 100%, 94.1%, 0%,
and 71.4%, respectively (Additional file 2). Probability of
reaching the target 100%ƒT > 4×MICECOFF was less than
25% for amoxicillin, cefotaxime, and cefuroxime, suggest-
ing that for all these drugs, inadequate drug concentra-
tions are obtained for pathogens with high MICs. Target
attainment for various beta-lactam antibiotics and dosing
regimens to reach the PDTs of 100% ƒT >MIC and 100%
ƒT > 4×MIC for a range of MICs (0.03125 to 128mg/L)
are shown in Fig. 2.
Predictors for target (non-)attainment
Predictor variables for target attainment were investigated
in the multivariate binary logistic regression (Table 2).
Variables associated with 100% ƒT >MICECOFF target at-
tainment include treatment with CRRT (OR 6.54, 95% CI
1.47–48.61) and high serum urea (OR 1.09, 95% CI 1.03–
1.17). Male gender, on the other hand, was found to be
significantly correlated with target non-attainment (OR
0.32, 95% CI 0.12–0.81). For the PDT 100% ƒT >
4×MICECOFF, target non-attainment was significantly
more observed in patients with baseline eGFR ≥ 90mL/
min/1.73m2 (OR 0.14, 95% CI 0.03–0.49) and high BMI
(OR 0.91, 95% CI 0.83–0.99). A high serum urea demon-
strated a significant association (OR 1.05, 95% CI 1.00–
1.10) with 100% ƒT > 4×MIC target attainment.
Predictors for clinical outcomes
Table 3 shows the estimates for the multivariate bino-
mial regression and binary logistic regression models
examining the association of target attainment with ICU
LOS and 30-day survival, respectively. The PDT of 100%
ƒT >MICECOFF was significantly associated with the clin-
ical outcome ICU LOS (OR 1.66, 95% CI 1.19–2.32). In
the multivariate models, the presence of CRRT was for
both PDTs significantly associated with higher ICU LOS
(OR, 2.08 [95% CI, 1.38–3.20] and OR, 2.13 [95% CI,
1.39–3.34], respectively). Furthermore, an eGFR ≥ 90
mL/min/1.73 m2 was associated with increased ICU LOS
in both PDT models (OR, 1.67 [95% CI, 1.13–2.47] and
OR, 1.69 [95% CI, 1.12–2.56], respectively). Finally, there
was no significant association for both models with the
30-day survival outcome (OR, 0.56 [95% CI, 0.19–1.66]
and OR, 1.24 [95% CI, 0.44–3.73], respectively).
Discussion
In this prospective study, we describe detailed target at-
tainment of six frequently used beta-lactam antibiotics
and risk factors for target non-attainment in critically ill
patients. Achievement of PK/PD targets was highly vari-
able in the beta-lactam antibiotics analyzed in this study
(Fig. 1), and the 100% ƒT >MICECOFF target was
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Table 1 Baseline demographic characteristics, clinical data, PK/PD indices, and clinical outcomes of all patients included and
between PDT attainment and non-attainment groups
Characteristics All patients (n = 147) PDT attainment (n = 93) PDT non-attainment
(n = 54)
p valuea
Demographic data
Age (years) 63 (56–70) 65.0 (58.5–73.0) 60.5 (51.0–66.0) 0.001
Sex (male/female) 91/56 51/42 40/14 0.021
Length (cm) 172.2 (10.7) 169.7 (10.1) 176.6 (10.3) < 0.001
Weight (kg) 77 (70–90) 75 (68–90) 80 (70–90) 0.339
BMI 26.1 (22.9–29.3) 26.9 (23.9–29.6) 25.3 (22.2–28.1) 0.087
Concomitant antibiotics 0.029
No 54 (36.7%) 28 (30.1%) 26 (48.1%)
Yesb 93 (63.3%) 65 (69.9%) 28 (51.9%)
Clinical data at inclusion
SOFA 11.0 [7.0–15.0] 0.293
0–6 28 (19.0%) 15 (16.3%) 13 (24.1%)
7–9 32 (21.8%) 18 (19.6%) 14 (25.9%)
10–14 38 (25.9%) 24 (26.1%) 14 (25.9%)
15 48 (32.7%) 35 (38.0%) 13 (24.1%)
APACHE II 23 [18–27] 0.161
0–9 5 (3.4%) 3 (3.3%) 2 (3.7%)
10–19 39 (26.7%) 20 (21.7%) 19 (35.2%)
20–29 85 (58.2%) 55 (59.8%) 30 (55.6%)
≥ 30 17 (11.6%) 14 (15.2%) 3 (5.6%)
Albumin (g/L) 26.3 (7.3) 24.9 (7.0) 28.5 (7.3) 0.003
Serum creatinine (μmol/L) 102 [67–155] 124.0 [79.5–182.5] 79.5 [56.8–106.3] < 0.001
Temperature (°C) 36.9 [36.1–37.4] 36.7 [36.0–37.3] 37.0 [36.3–37.6] 0.112
WBC (× 109/L) 13.2 [8.7–18.2] 11.7 [7.3–17.8] 15.8 [10.7–20.2] 0.022
CRP (mg/L) 111 [35–226] 120 [46–242] 91 [15–175] 0.072
Serum urea (mmol/L) 8.9 [6.1–16.5] 12.4 [7.1–19.2] 6.6 [4.8–9.3] < 0.001
eGFR (mL/min/1.73 m2) < 0.001
< 30 29 (19.7%) 25 (26.9%) 4 (7.4%)
30–50 31 (21.1%) 28 (30.1%) 3 (5.6%)
50–90 41 (27.9%) 19 (20.4%) 22 (40.7%)
> 90 46 (31.3%) 21 (22.6%) 25 (46.3%)
CRRT 0.063
No 119 (81%) 71 (76.3%) 48 (88.9%)
Yes 28 (19%) 22 (23.7%) 6 (12.1%)
PK/PD indices
%ƒT > MICECOFF 84.2%
%ƒT > 4×MICECOFF 51.7%
Clinical outcomes
ICU LOS (days) 9 [4–15] 11 [6–20] 5 [3–12.8] 0.005
30-day mortality 29 (19.7%) 22 (24.2%) 7 (13.2%) 0.135
Values are presented as numbers (%), median [25%–75% interquartile range], or mean (± standard deviation). The numbers in bold are statistically significant
APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CRP C-reactive protein, CRRT continuous renal replacement therapy, ECOFF
epidemiological cut-off value, eGFR estimated glomerular filtration rate, calculated with the CKD-EPI Creatinine Equation, ƒT > MIC the unbound concentrations
above the minimum inhibitory concentration, ICU LOS intensive care unit length of stay, calculated from the start of study antibiotic until ICU discharge, PDT
pharmacodynamic target, SOFA score Sequential Organ Failure Assessment score, WBC white blood cell count
aThe p value between target attainment versus non-attainment patient population and the value in bold indicates a significant difference between the two
groups (p ≤ 0.05)
bOne or more additional antibiotics
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achieved in 63.3% of the study population. We identified
male gender, high BMI, and high eGFR as risk target
non-attainment in our study population. Moreover, we
found a significant association between the 100%ƒT >
MICECOFF target attainment and ICU LOS, but no sig-
nificant correlation was found for the 30-day survival.
Roberts et al. found that critically ill patients failing to
attain even the most conservative beta-lactam exposure
target of 50% ƒT >MIC were 32% less likely to have a
positive clinical outcome (defined as completion of treat-
ment course without change or addition of antibiotic
therapy) [21]. In addition, they found an association be-
tween positive clinical outcome and an increasing 100%
ƒT >MIC ratio (OR 1.53, p = 0.03) [21]. Considering that
critically ill patients are vulnerable to suboptimal dosing
and represent a source of selection of resistance to anti-
biotics, we also assessed the probability of 100% ƒT >
4×MICECOFF target attainment, as this would allow for
the maximal bacterial killing and also protect against
bacterial regrowth [34–36]. In our study, the 100% ƒT >
4×MICECOFF target was achieved in only 36.7% of the
patients.
Antimicrobial dosing in critically ill patients requires
consideration of drug distribution and clearance in the
setting of end-organ failure, fluctuations in fluid status,
and drug interactions. However, the findings of our
study suggest that target attainment during beta-lactam
therapy in critically ill patients may be anticipated at the
bedside prior to antibiotic initiation. Predictor variables
in the multivariate analysis associated with increased
odds for target non-attainment were male gender and
eGFR (Table 2). These associations in critically ill pa-
tients treated with beta-lactam antibiotics are in line
with previous studies [25–27].
The observed effect of gender on drug exposure can
be explained by the fact that, on average, greater volume
of distribution (plasma volume and intra-/extracellular
water) and higher drug clearance is observed in men
[37]. Although gender is easy to implement in risk factor
models for target non-attainment, future studies should
be designed with a primary focus on this topic to better
understand of the basic mechanisms of gender differ-
ences and the implications for clinical management [37].
In our study population, the probability of the
100%ƒT>4×MIC target non-attainment was significantly
associated with an eGFR ≥ 90mL/min/1.73 m2 (OR 0.14,
95% CI 0.03–0.49) at inclusion. eGFR calculated on
serum creatinine is the best surrogate marker of renal
clearance. In total, 31.3% of our population had an eGFR
≥ 90mL/min/1.73 m2, while 46.3% in the non-attainment
group did so (Table 2). This means that patients with
presumed “normal” or elevated renal function are at risk
of target non-attainment and need to be identified early
so that appropriate dose adjustment can be made. More-
over, Imani et al. assessed the performance of eGFR as
an independent predictor for target non-attainment
using a ROC curve and found an eGFR threshold value
of ≥ 71.5 mL/min/1.73 m2 had a sensitivity and specificity
of 77% and 65%, respectively [26]. As beta-lactam antibi-
otics are predominantly cleared by the kidney, high renal
function (eGFR ≥ 130 mL/min), as observed in aug-
mented renal clearance (ARC), contributes even more to
suboptimal PK/PD target attainment. ARC is observed
in 30–65% of patients during the first week in the ICU
[14, 38, 39], and both age and male gender are inde-
pendently associated with ARC [39]. Moreover, ARC is a
strong predictor for one or more undetectable trough
concentrations [OR 3.3, 95% CI 1.11–9.94] [14]. Carrié
et al. reported that eGFR ≥ 170 mL/min were signifi-
cantly associated with T<4×MIC [OR 10.1; (2.4–41.6);
p = 0.001] [24]. The ability to rapidly predict the risk of
target non-attainment in patients with ARC using avail-
able eGFR has considerable clinical value.
Furthermore, in the multivariate analysis, we found a
strong and significant association between target attain-
ment and treatment with CRRT. To our knowledge, this
is the only study where in a multivariate analysis this as-
sociation was demonstrated. Not surprisingly, consider-
ing that beta-lactams are predominantly cleared via
Fig. 1 Box (median, 25th and 75th percentiles) and whisker (10th and
90th percentiles) plots of unbound trough (ƒCmin) plasma concentrations
observed in critically ill patients treated with beta-lactam antibiotics. The
green areas indicate the target exposure (ƒCmin = 1–10×MICECOFF), the blue
areas indicate suboptimal exposure (ƒCmin <1×MICECOFF), and the red areas
indicate threshold for dose reduction (ƒCmin > 10×MICECOFF). The numbers
of trough samples (n) are presented per antibiotic. Outliers are removed
using the ROUT method (Q=0.5%). Filled circles are remaining outliers.
*Amoxicillin and amoxicillin/clavulanic acid
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Fig. 2 (See legend on next page.)
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renal elimination. At the same time, these patients may
be at risk for overexposure and toxicity due to the re-
duced elimination. However, predicting beta-lactam con-
centrations during treatment with CRRT is challenging,
as both volume of distribution and total drug clearance
are affected, and both parameters may be significantly
disturbed during critical illness. In addition, it is import-
ant to realize that the effect of CRRT on target attain-
ment may be unpredictably affected by for example the
type of membrane, device settings, and intensity [40].
Evidence regarding relevant predictor variables with
clinical outcomes in critically ill patients are still limited.
Huttner et al. found that ARC was associated with un-
detectable beta-lactam antibiotic trough concentrations,
but failed to demonstrate a link between ARC or low
beta-lactam trough concentrations with clinical failure
[14]. In contrast, Carrié et al. reported that beta-lactam
underexposure was associated with higher rates of thera-
peutic failure in septic critically ill patients [24]. In our
population, we found a significant association for the
100% ƒT >MICECOFF PDT model with the clinical out-
come ICU LOS. The link with this outcome is a new
finding. Interestingly, the ICU LOS increases as 100%
ƒT >MIC is achieved. This is also reflected in the
significant difference of the median admission days in
both groups (Table 1). An explanation for the target at-
tainment association with ICU LOS may be the fact that
the elderly and the most ill patients in our population
stayed longer at the ICU. These patients have relatively
worse end-organ functions (including renal clearance)
and therefore have higher exposure and are more on-
target. Patients who died could have had an effect on the
outcomes of the predictive LOS models. Therefore, we
also performed the binomial regression models while ex-
cluding the non-survivors (data not presented). How-
ever, this had no effect on the significant variables found
in both PDT models. Furthermore, in both PDT models,
CRRT was significantly associated with higher ICU LOS.
In addition, eGFR ≥ 90 mL/min/1.73 m2 was independ-
ently and convincingly associated with increased ICU
LOS in both PDT models (Table 3). It should be noted
that patients receiving CRRT (n = 28) at any time during
the antibiotic therapy were not excluded from this ana-
lysis. However, an eGFR ≥ 90 mL/min/1.73 m2 was still
independently associated with increased ICU LOS when
patients on CRRT are excluded (data not shown). Al-
though increased renal clearance and ARC is highly
prevalent in critically ill patients, in practice, clinicians
may fail to address this as a risk factor and prescribe
standard beta-lactam dosing. Indeed, the complexity and
dynamic nature of critically ill patients and the hetero-
geneity in their pharmacokinetic response make associa-
tions of clinical variables and the calculated risk of target
non-attainment of beta-lactam antibiotics difficult to
apply without supporting tools.
Therapeutic drug monitoring (TDM) combined with
population PK models with appropriate co-variables can
be used to interpret the complex PK in critically ill pa-
tients and to support in optimizing individual dosing to
improve predefined targets [41–43]. However, the lack
of guidelines, long turnaround times, and limited access
to beta-lactam TDM services are potential barriers to its
implementation [44]. Routine TDM with same-day anti-
biotic dose adaptation using immunoassays over the
more commonly used chromatographic methods could
contribute to overcoming these barriers in routine clin-
ical practice [45]. However, pending a large randomized
trial investigating the effect of TDM of beta-lactam anti-
biotics on clinical outcome in critically ill patients [46],
the clinical impact on patient’s prognosis using this
strategy is not yet fully demonstrated. In view of the fact
(See figure on previous page.)
Fig. 2 Target attainment in ICU patients for various beta-lactams and dosing regimens to reach the PDTs 100% ƒT >MIC (A1–F1) and 100% ƒT >
4×MIC (A2–F2) for a range of MICs. The numbers of patients (n) are presented per antibiotic and dose regimen. The dotted horizontal line
indicates the intercept with the EUCAST epidemiological cut-off (ECOFF) breakpoints: amoxicillin 8 mg/L (Enterobacterales), cefotaxime 4mg/L
(Staphylococcus aureus), ceftazidime 8mg/L (Pseudomonas aeruginosa), ceftriaxone 0.5 mg/L (Enterobacterales), cefuroxime 8 mg/L (Escherichia coli),
and meropenem 2mg/L (Pseudomonas aeruginosa)
Table 2 Multivariate binary logistic regression in ICU patients,
analysis predicting attainment achieving PDT of (A) 100% ƒT >
MIC and (B) 100% ƒT > 4×MIC as the dependent factor
Predictor variables 100% ƒT >MIC 100% ƒT > 4×MIC
OR (95% CI) OR (95% CI)
Male gender 0.32 (0.12–0.81) 0.60 (0.23–1.51)
Age (years) 1.03 (0.99–1.07) 0.98 (0.94–1.01)
BMI (mg/kg2) 0.98 (0.91–1.05) 0.91 (0.83–0.99)
Serum urea (mmol/L) 1.09 (1.03–1.17) 1.05 (1.00–1.10)
eGFR ≥ 90 (mL/min/1.73 m2) 0.69 (0.25–1.94) 0.14 (0.03–0.49)
SOFA score 1.05 (0.96–1.16) 0.95 (0.85–1.05)
CRRT 6.54 (1.47–48.61) 2.26 (0.73–6.97)
Sepsis 1.18 (0.38–3.88) 1.31 (0.43–3.88)
The estimates are odds ratios (ORs) and 95% confidence intervals. The
numbers in bold are statistically significant. Statistical significance was
accepted at p ≤ 0.05. McFadden R-squared for models A and B are 0.21 and
0.18, respectively, representing good fit
BMI body mass index, CRRT continuous renal replacement therapy, eGFR
estimated glomerular filtration rate calculated with the CKD-EPI Creatinine
Equation, ƒT > MIC the unbound concentrations above the minimum inhibitory
concentration, PDT pharmacodynamic target, SOFA score Sequential Organ
Failure Assessment score
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that target attainment is observed in only about 60–65%
of critically ill patients receiving antibiotics and consid-
ering the increasing resistance to antibiotics worldwide,
higher dosing in these patients could be an alternative
strategy to obtain better target attainment when TDM is
not available. Carrie et al. showed that, in critically ill pa-
tients with ARC, higher than licensed dosing regimens
of beta-lactam antibiotics may be safe and effective in re-
ducing the rate of therapeutic failure [47]. Moreover,
Imani et al. found that prescribed daily antibiotic dose ≥
1.5 times the product information recommendations was
associated with better target attainment [26]. Toxicity
concerns as a result of drug accumulation are valid, but
less pertinent given that toxicity thresholds are high for
beta-lactam antibiotic agents [23]. However, serious ad-
verse drug reactions related to excessively high serum
levels have recently been reported, which further under-
scores a potential added value of TDM in critically ill
patients [48–51]. Furthermore, to avoid high (peak)
serum levels of beta-lactam antibiotics, prolonged or
continuous infusion is an alternative dosing strategy to
maximize target achievement and is likely to improve
clinical outcomes in critically ill patients [52].
The current study has some limitations that should be
noted. First, we have measured total drug concentrations
with correction for protein binding based on the litera-
ture. Measuring unbound concentrations is desirable in
critically ill patients, since the ratio of bound and un-
bound drugs can be subjected to changes because of
disease characteristics of these patients. However, with
the exception of ceftriaxone, the protein binding of most
antibiotics in this study is too low to be clinically af-
fected by, for example, a decreased serum albumin.
Moreover, we analyzed unbound concentration of ceftri-
axone in another cohort of critically ill patients [46] to
support the clinical feasibility of calculating unbound
fractions using an average PPB value. The mean fraction
of ceftriaxone unbound plasma concentrations (n = 34)
in the range of 0.05–40mg/L was 12.3% [IQR 8.5–20]
(unpublished observations), which is comparable to the
calculated unbound concentration used in this study and
previously published data [31]. Second, MIC values were
assumed from population estimates (ECOFF values) to
calculate target attainment. Due to this approach, there
is a chance that target attainment is underestimated in
our study. Furthermore, the use of a measured MIC ob-
tained by a single MIC determination is debatable, since
routine clinical laboratories cannot determine MICs with
sufficient accuracy due to the inherent assay variation in
the MIC test and the variation in any MIC determin-
ation [53]. Although the ECOFF is in many situations
similar to the clinical breakpoint, it is still important to
closely evaluate the PK/PD target against the local drug
resistance epidemiology. Third, we were not able to per-
form direct urinary creatinine measurements based on
24-h urine collections. We estimated serum creatinine
clearance using the CKD-EPI Creatinine Equation for-
mula, which is not validated for critically ill patients.
Table 3 Multivariate regression models in ICU patients for PDT attainment and odds ratio estimates for the association with the
clinical outcomes (A) ICU LOS and (B) 30-day survival
Models and variables ICU LOSa
OR (95% CI)
30-day survivalb
OR (95% CI)
Regression model, PDT: 100% ƒT >MIC 1.66 (1.19–2.32) 0.58 (0.19–1.66)
Age (years) 0.99 (0.98–1.01) 1.02 (0.98–1.05)
CRRT 2.08 (1.38–3.20) 0.41 (0.13–1.33)
Sepsis 0.91 (0.61–1.37) 0.90 (0.30–2.86)
Serum urea (mmol/L) 1.00 (0.99–1.02) 1.05 (0.99–1.11)
SOFA score 1.00 (0.96–1.03) 0.95 (0.85–1.05)
eGFR ≥ 90 (mL/min/1.73 m2) 1.67 (1.13–2.47) 1.97 (0.66–6.88)
Regression model, PDT: 100% ƒT > 4×MIC 1.26 (0.88–1.82) 1.24 (0.44–3.73)
Age (years) 1.00 (0.98–1.01) 1.01 (0.98–1.05)
CRRT 2.13 (1.39–3.34) 0.35 (0.11–1.11)
Sepsis 0.89 (0.59–1.34) 0.91 (0.31–2.88)
Serum urea (mmol/L) 1.01 (0.99–1.03) 1.04 (0.98–1.10)
SOFA score 1.01 (0.97–1.05) 0.94 (0.84–1.05)
eGFR ≥ 90 (mL/min/1.73 m2) 1.69 (1.12–2.56) 2.09 (0.66–7.22)
The estimates are odds ratios (ORs) and 95% confidence intervals. The numbers in bold are statistically significant. Statistical significance was accepted at p ≤ 0.05
CRRT continuous renal replacement therapy, eGFR estimated glomerular filtration rate, ICU LOS intensive care unit length of stay, calculated from the start of study
antibiotic until ICU discharge, PDT pharmacodynamic target, SOFA Sequential Organ Failure Assessment
aNegative binomial regression model
bBinary logistic regression model
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However, it is unlikely that the study population with an
eGFR ≥ 90mL/min/1.73m2 would in fact have had im-
paired renal function if calculated with urinary creatinine.
Thus, we assume that possible misclassification of creatin-
ine clearance did not invalidate our main observations.
Fourth, we are aware that, in our regression models, base-
line characteristics and target attainment were measured
at two time points in the study period, respectively at in-
clusion and day of sampling. However, it is important to
include some control variables that reflect the baseline
characteristics of the patients. Finally, in the study popula-
tion, cephalosporins, in particular cefotaxime, were over-
represented compared with the other classes of beta-
lactam antibiotics. Target attainment and associated risk
factors of the different antimicrobial agents in this context
thus remain to be determined by more specific studies.
Conclusions
This study provides additional PDT attainment data and
risk factors associated with target non-attainment to sup-
port beta-lactam antibiotic dosing in critically ill patients.
Traditional beta-lactam antibiotic dosing results in low
target attainment, less than two-thirds of our study popu-
lation achieved the 100% ƒT >MICECOFF target and only
one-third the 100% ƒT>4×MICECOFF target. Target attain-
ment during beta-lactam therapy in critically ill patients
may be anticipated at the bedside using predictor vari-
ables. Male patients with apparently normal or increased
renal function and the use of CRRT were strong predic-
tors of beta-lactam antibiotic exposure. Our data suggest
that patients with eGFR ≥ 90mL/min/1.73m2 are at risk
of target non-attainment, and this is associated with in-
creased ICU LOS. Based on our data, we recommend
TDM, selectively applied based on the described risk fac-
tors, during the early stages of beta-lactam therapy in crit-
ically ill patients. Whether these patients would benefit
from more individualized dosing regimens should be eval-
uated by randomized controlled studies.
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